医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Glaukos Announces Pharmaceutical Development Agreement with D. Western Therapeutics Institute, Inc.

2018年08月03日 AM05:15
このエントリーをはてなブックマークに追加


 

SAN CLEMENTE, Calif.

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, today announced it has entered into a research and development collaboration agreement with D. Western Therapeutics Institute (DWTI), a Japanese biotechnology company focused on the discovery and development of innovative new drugs to serve patients worldwide.

Under the agreement, Glaukos and DWTI will conduct joint research for the development of novel intraocular products for the treatment of glaucoma using compounds from DWTI’s proprietary ROCK inhibitor compound library, one of DWTI’s fundamental technologies, and potentially design and synthesize new compounds for this collaboration. Glaukos will conduct the evaluation and development of the compounds.

“We are delighted to enter into this collaboration with D. Western, which has a proven track record of novel drug discovery and is highly regarded in the industry as the preeminent research organization for proprietary ROCK inhibitor compounds,” said Thomas Burns, Glaukos president and chief executive officer. “We are excited to commence the initial phases of this collaborative research effort to explore potential new compounds that may be used in our novel iDoseTM drug delivery system in order to expand and improve the treatment of glaucoma.”

Per the agreement, DWTI will receive an upfront technology access fee and research support fees from Glaukos. In addition, if one or more candidate compounds are identified, Glaukos holds the exclusive right to develop novel intracameral and topical products using the compounds through a licensing arrangement with DWTI.

Glaucoma is characterized by progressive, irreversible and largely asymptomatic vision loss caused by optic nerve damage. There is no cure for the disease and reducing IOP is the only proven treatment. Based on analysis of population-based surveys, medical claims data and other statistics, the company estimates that there are approximately 5.4 million people in the U.S. with primary open-angle glaucoma, the most common form of the disease.

About D. Western

D. Western Therapeutics Institute is a Japanese biotechnology company that focuses on the discovery and development of innovative new drugs to serve patients worldwide. Its research and development laboratory undertakes drug design, screening of compounds and selection of prospect compounds at early stages of the drug research and development process. DWTI’s seed compounds are inhibitors of protein kinases the company has accumulated in the past. The company creates effective drug candidate compounds by advancing development of such inhibitors that control the function of the protein kinase. The company was founded by Hiroyoshi Hidaka in February 1999 and is headquartered in Nagoya, Japan. Shares of DWTI are publicly traded on the Tokyo Stock Exchange (TSE).

About Glaukos

Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, one of the world’s leading causes of blindness. The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. Glaukos launched the iStent®, its first MIGS device, in the United States in July 2012 and is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale injectable therapies designed to address the complete range of glaucoma disease states and progression. The company believes the iStent inject®, measuring 0.23 mm wide and 0.36 mm long, is the smallest medical device ever approved by the FDA.

Forward-Looking Statements

All statements other than statements of historical facts included in this press release that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. Although we believe that we have a reasonable basis for forward-looking statements contained herein, we caution you that they are based on current expectations about future events affecting us and are subject to risks, uncertainties and factors relating to our operations and business environment, all of which are difficult to predict and many of which are beyond our control, that may cause our actual results to differ materially from those expressed or implied by forward-looking statements in this press release. These potential risks and uncertainties include, without limitation, the extent to which the joint research to be conducted by Glaukos and DWTI pursuant to the research and development agreement will result in the development of any novel intraocular products or compounds for the treatment of glaucoma; and the extent to which Glaukos will be able to develop or otherwise obtain any new compounds that may be used in our novel iDoseTM drug delivery system; and whether Glaukos would obtain the necessary regulatory approvals to commercialize any new compounds. These risks, uncertainties and factors are described in detail under the caption “Risk Factors” and elsewhere in our filings with the Securities and Exchange Commission, including our Quarterly Report on Form 10-Q for the quarter ended March 31, 2018 filed with the Securities and Exchange Commission. Our filings with the Securities and Exchange Commission are available in the Investor Section of our website at www.glaukos.com or at www.sec.gov. In addition, information about the risks and benefits of our products is available on our website at www.glaukos.com. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on the forward-looking statements in this press release, which speak only as of the date hereof. We do not undertake any obligation to update, amend or clarify these forward-looking statements whether as a result of new information, future events or otherwise, except as may be required under applicable securities law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180802005719/en/

CONTACT

Glaukos Corporation
Media Contact:
Cassandra Dump
(619)
971-1887
cassy@pascalecommunications.com
or
Investor
Contact:

Chris Lewis
Director, Investor Relations,
Corporate Development & Strategy
(949) 481-0510
clewis@glaukos.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Brightree发布面向居家医疗器械的首个患者App
  • Brightreeが初のHME向け患者アプリを発表
  • Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer
  • ポットネットワーク・ホールディングスがSEC報告会社登録に基づきPCAOB監査人による完全な監査・レビュー済みの財務報告書を公表
  • Takeda Receives Clearance from the Japan Fair Trade Commission for the Proposed Acquisition of Shire plc